Warning Letters Signal Steps to Compliance

Warning letters tell the tale of missteps by drug companies and offer a path to compliance for quality teams that monitor these enforcement actions.

While the number of warning letters issued by FDA has declined slightly, recurrent violations include poorly maintained equipment and facilities, insufficient cleaning validation, inadequate written procedures for quality testing, and inadequate controls over data and computer systems. Effective, ongoing monitoring programs-for regulatory agency enforcement actions and pharmacopoeia updates-are essential for bio/pharma compliance.

Read this article in Pharmaceutical Technology’s December 2019 Regulatory Sourcebook.

Article Details

Pharmaceutical Technology
eBook: Regulatory Sourcebook, December 2019
December 2019
Pages: 4–5

Citation

When referring to this article, please cite it as R. Peters, “Warning Letters Signal Steps to Compliance," Pharmaceutical Technology Regulatory Sourcebook eBook (December 2019).

Articles in this issue

almost 6 years ago

Article

Revision Process for Global/National Pharmacopoeias (eBook)

almost 6 years ago

Article

Regulatory and Standard Setting Organizations

almost 6 years ago

Article

Resources, Guidelines, and Guidance Documents

almost 6 years ago

Article

Design of Experiments Gains Ground in Biopharma Development

almost 6 years ago

Article

Quality Risk Management Plans Create Effective Quality Systems

almost 6 years ago

Article

Moving from Compliance to Quality

almost 6 years ago

Article

Surveillance Process for Industry: Monitoring Pharmacopoeia Revisions (eBook)

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!